Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity

In the original article, there was an error. The concentration and administration schedule of Rapalink-1 reported for in vivo experiment not correct. error appeared both "Materials Methods" "Results" sections, where it is incorrectly as "1.5 mg/g […] every 5 days" mg/g/6 days", respectively. Figure 5C article correct schedule.A correction has been made to section, "Animals Maintenance Experiment" sub-section:"Group 1 received 3.5 μl/g vehicle (20% DMSO, 40% PEG-300 PBS) i.p. once a week while group 2 (1.5 mg/Kg) resuspended vehicle, 5-7 days."A same "Treatment LAPC9 With Delays Tumor Growth" sub-section:"We then assessed effect on PDX model, comparing treatment only, schematic ( 5C)."The authors apologize this state that does change scientific conclusions any way. updated.